SymBiosis Capital Partners, LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 12, 2026), SymBiosis Capital Partners, LLC reported 5 stock positions worth $52.8 million. Its top holding was Evommune (EVMN) at 55.8% of the portfolio, followed by Inventiva SA - ADR (IVA, 24.8%) and Wave Life Sciences (WVE, 10.3%). Compared with Q4 2025, it opened 1 new position, sold out of 6 and reduced 3. The biggest buy was a new position in Wave Life Sciences (WVE) and the biggest sale an exit from Verastem (VSTM).

Most Recent 13F
Q1 2026
Location
BENTONVILLE, AR
CIK
0002006045
Portfolio Value
$52.8M (Q1 2026)
SEC Filing
0002006045-26-000007 ↗ filed May 12, 2026

Holdings Value

0$50.0M$100.0M$150.0M Q4 2025: $109.5M Q4 2025 Q1 2026: $52.8M $52.8M Q1 2026

Holdings 5 stocks · $52.8M
EVMN Evommune Inc. 55.80% 1,280,778 $29.4M No change
IVA Inventiva SA - ADR 24.76% 2,354,000 $13.1M Reduce -9.5%
WVE Wave Life Sciences Ltd. 10.30% 750,000 $5.4M New
RANI Rani Therapeutics Holdings Class A 5.11% 3,667,585 $2.7M Reduce -41.8%
CLNN Clene Inc. 4.03% 431,094 $2.1M Reduce -44.0%
Other holdings (1): bonds, preferreds, convertibles and warrants · $2K (not counted above)
SecurityClassShares / PrincipalValueChange
SRZNW Surrozen Inc.-CW25 *W EXP 08/01/203 150,000$2KNo change

Total filed on the 13F, all lines: $52.8M.

Portfolio Sells Q4 2025 → Q1 2026
VSTM Verastem Inc. Sold out 0.00% −14.10
AMPG Amplitech Group Inc. Sold out 0.00% −12.09
PGEN Precigen Inc. Sold out 0.00% −11.45
NUVB Nuvation Bio Inc. Sold out 0.00% −10.23
AARD Aardvark Therapeutics Inc. Sold out 0.00% −5.71
GBIO Generation Bio Co. Sold out 0.00% −3.45
RANI Rani Therapeutics Holdings Class A Reduce -41.8% 5.11% −2.66
CLNN Clene Inc. Reduce -44.0% 4.03% −0.10
IVA Inventiva SA - ADR Reduce -9.5% 24.76% +13.72

Portfolio Buys Q4 2025 → Q1 2026
WVE Wave Life Sciences Ltd. New 10.30% +10.30

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q1 2026 5$52.8MEVMN, IVA, WVE, RANI, CLNN
Q4 2025 10$109.5MEVMN, VSTM, AMPG, PGEN, IVA